Have your own idea? Try our Stock Screener
U.K. (FTSE) Clinical Research and Equipment Industry Analysis
UpdatedDec 16, 2025
DataAggregated Company Financials
Companies8
- 7D-4.1%
- 3M-20.5%
- 1Y-24.1%
- YTDn/a
Over the last 7 days, the Clinical Research and Equipment industry has remained flat, although notably Fusion Antibodies gained 26%. As for the longer term, the industry has declined 23% in the last year. Earnings are forecast to grow by 42% annually.
Industry Valuation and Performance
Has the U.K. Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 16 Dec 2025 | UK£1.4b | UK£304.4m | -UK£160,881,254.00 | 8.5x | -8.7x | 4.6x |
| Thu, 13 Nov 2025 | UK£1.5b | UK£304.3m | -UK£163,156,254.00 | 8.2x | -9.4x | 5.1x |
| Sat, 11 Oct 2025 | UK£1.6b | UK£304.3m | -UK£163,156,254.00 | 8.9x | -10x | 5.4x |
| Mon, 08 Sep 2025 | UK£1.8b | UK£313.5m | -UK£158,190,352.00 | 6.5x | -11.3x | 5.7x |
| Wed, 06 Aug 2025 | UK£2.3b | UK£291.9m | -UK£160,968,352.00 | 6.4x | -14.4x | 7.9x |
| Fri, 04 Jul 2025 | UK£1.6b | UK£291.9m | -UK£160,968,352.00 | 6.9x | -10.1x | 5.6x |
| Sun, 01 Jun 2025 | UK£1.6b | UK£319.6m | -UK£190,958,890.00 | 5.6x | -8.2x | 4.9x |
| Tue, 29 Apr 2025 | UK£1.6b | UK£313.6m | -UK£192,087,556.40 | 11.2x | -8.4x | 5.1x |
| Thu, 27 Mar 2025 | UK£1.5b | UK£315.7m | -UK£186,310,515.95 | 5.8x | -7.9x | 4.7x |
| Sat, 22 Feb 2025 | UK£1.7b | UK£306.4m | -UK£195,106,167.60 | 6.9x | -8.9x | 5.7x |
| Mon, 20 Jan 2025 | UK£2.1b | UK£307.8m | -UK£196,207,193.76 | 7.1x | -10.5x | 6.7x |
| Wed, 18 Dec 2024 | UK£2.1b | UK£306.2m | -UK£194,946,070.32 | 7.7x | -10.8x | 6.8x |
| Fri, 15 Nov 2024 | UK£1.9b | UK£305.7m | -UK£193,463,506.72 | 10.4x | -10.1x | 6.4x |
| Sun, 13 Oct 2024 | UK£2.0b | UK£304.4m | -UK£192,350,536.90 | 10.6x | -10.4x | 6.6x |
| Tue, 10 Sep 2024 | UK£2.0b | UK£293.5m | -UK£192,442,081.20 | 12.1x | -10.4x | 6.9x |
| Thu, 08 Aug 2024 | UK£1.9b | UK£297.0m | -UK£189,319,026.11 | 12.3x | -9.9x | 6.3x |
| Sat, 06 Jul 2024 | UK£1.6b | UK£295.5m | -UK£189,930,390.09 | 11.7x | -8.2x | 5.3x |
| Mon, 03 Jun 2024 | UK£1.6b | UK£295.6m | -UK£189,808,553.55 | 11.3x | -8.6x | 5.5x |
| Wed, 01 May 2024 | UK£1.5b | UK£292.9m | -UK£189,023,379.29 | 6973.2x | -7.7x | 5x |
| Fri, 29 Mar 2024 | UK£1.8b | UK£319.1m | -UK£191,397,787.59 | 69.8x | -9.2x | 5.5x |
| Sun, 25 Feb 2024 | UK£1.9b | UK£285.8m | -UK£189,209,049.14 | 6964.3x | -10.3x | 6.8x |
| Tue, 23 Jan 2024 | UK£2.9b | UK£450.2m | -UK£176,575,158.00 | 61.5x | -16.2x | 6.4x |
| Thu, 21 Dec 2023 | UK£3.2b | UK£450.1m | -UK£174,131,391.00 | 52.7x | -18.2x | 7x |
| Sat, 18 Nov 2023 | UK£3.0b | UK£455.8m | -UK£168,941,726.00 | 50.3x | -18x | 6.7x |
| Mon, 16 Oct 2023 | UK£2.9b | UK£458.7m | -UK£165,688,739.00 | 51.1x | -17.6x | 6.3x |
| Wed, 13 Sep 2023 | UK£3.1b | UK£440.4m | -UK£166,942,738.00 | 67.5x | -18.4x | 7x |
| Fri, 11 Aug 2023 | UK£3.4b | UK£476.1m | -UK£126,508,300.00 | 70.6x | -27.1x | 7.2x |
| Sun, 09 Jul 2023 | UK£2.9b | UK£476.3m | -UK£124,539,981.00 | 66.1x | -23.4x | 6.1x |
| Tue, 06 Jun 2023 | UK£3.3b | UK£477.0m | -UK£117,020,631.00 | 65.2x | -28.6x | 7x |
| Thu, 04 May 2023 | UK£3.1b | UK£480.0m | -UK£117,198,894.00 | 35.9x | -26.6x | 6.5x |
| Sat, 01 Apr 2023 | UK£3.0b | UK£459.0m | -UK£119,153,393.00 | 34.4x | -25.5x | 6.6x |
| Mon, 27 Feb 2023 | UK£3.1b | UK£444.0m | -UK£183,285,157.00 | 43.7x | -17x | 7x |
| Wed, 25 Jan 2023 | UK£3.5b | UK£442.9m | -UK£182,677,717.00 | 49.3x | -19x | 7.8x |
| Fri, 23 Dec 2022 | UK£3.5b | UK£443.7m | -UK£183,063,688.00 | 49.9x | -18.9x | 7.8x |
Price to Earnings Ratio
-18.9x
Current Industry PE
- Investors are pessimistic on the British Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 6.2x is higher than the industry's current PS ratio of 4.6x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have improved over the last three years.
- Meanwhile revenues for these companies have declined 12% per year.
- This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.
Industry Comparison
How does U.K. Clinical Research and Equipment compare with similar industries?
| GB Market | 1.08% | |
| Healthcare | 0.34% | |
| Life Sciences | -4.10% | |
| Clinical Research and Equipment | -4.10% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| HVO hVIVO | UK£0.066 | 37.5% +UK£12.2m | -68.2% | PE8.5x | |
| FAB Fusion Antibodies | UK£0.17 | 14.8% +UK£2.6m | 165.2% | PS12.5x | |
| IXI IXICO | UK£0.12 | 9.3% +UK£926.7k | 2.2% | PS1.7x | |
| GDR genedrive | UK£0.0092 | 2.8% +UK£257.4k | -58.9% | PS10x |
